

Corporate Profile

We are a global healthcare company focused on Interventional Medicine. Our mission is to provide imaginative new ways to treat disease; making a real difference for patients, and a valuable contribution to healthcare.

Today we have a growing portfolio of products that advance the treatment of cancer, vascular conditions. Our Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins.

As medicine moves from major surgery to minor procedure, no company endeavours to do more to help doctors in their quest to see more, reach further and treat smarter. We understand their needs and equip them with tools and techniques that would have seemed like science fiction only a generation ago. We invest in clinical evidence that helps demonstrate the value of our treatments to patients, doctors, and healthcare systems.

With relentless curiosity we'll work with clinicians to find elegant new ways to extend our power over disease and transform patient care. There are no limits to where our ideas will take us.

At a Glance

Key Facts

- Leading specialist healthcare business
- 1600+ employees in North America, Europe, Asia and Australia
- Listed on London Stock Exchange (BTG.L)

Financial Highlights

For the year ended 31 March 2018

Revenue	\$822.8m
Adjusted operating profit	\$201.8m
Major Contributors to Revenue	
Interventional Medicine	\$322.7m
Pharmaceuticals	\$238.5m
Licensing	\$261.8m

Interventional Medicine

Interventional Medicine aims to pinpoint the problem inside the body and deliver ingenious treatments exactly where they're needed most. This is a fast-growing area of medicine driven by demand for better treatments and outcomes, by advances in imaging techniques and by product innovation.

Interventional Oncology

We develop products used in minimally invasive procedures to treat or provide symptomatic relief for people with cancer and benign tumours, targeting diseased cells while decreasing the impact on healthy tissue.

Our bead products block arteries (embolisation) that feed liver and other hypervascularised tumours, depriving them of blood and nutrients. Where approved, our drug-eluting beads also deliver a chemotherapeutic drug directly to the tumour.

Our radiotherapy product consists of millions of small glass microspheres that deliver radiation directly to liver tumours.

We use ultra-thin needles cooled to extremely low temperatures to freeze and destroy diseased cells in bone and soft tissue, kidney, liver, lung and prostate. Cryoablation for treating pain can be an effective way to manage painful conditions and provide palliative care.

Vascular

We help interventional vascular teams to solve problems with patients' veins and arteries.

Our ultrasonic devices help to dissolve blood clots and restore blood flow in patients with pulmonary emboli, deep vein thrombosis, and peripheral arterial occlusions.

We have developed an injectable microfoam for the treatment of patients with varicose veins.


We recently launched the world's first bioconvertible inferior vena cava (IVC) filter to prevention pulmonary embolism (PE) in patients at high risk of venous thromboembolic events, without the need to retrieve the device.

We provide anchoring catheters and microcatheters used to cross complex lesions and arterial blockages.

Pharmaceuticals

We provide antidotes that counteract the potentially life-threatening effects associated with exposure or overexposure to certain toxins. These acute care products are typically used in emergency rooms and intensive care units to treat patients for whom there are limited or no existing treatment options. We are dedicated to delivering quality medicines that make a real difference to patients through the development, manufacture, and commercialisation of pharmaceutical products. We actively seek opportunities to license or acquire additional products that enable healthcare providers to better serve their patients.

Our Journey



BTG Around the Globe

North America

- 1 Seattle, WA
- 2 Santa Clara, CA
- Redwood City, CA
- 3 Salt Lake City, UT
- 4 Arden Hills, MN
- 5 Ottawa, ON
- 6 Philadelphia, PA

Europe


- 7 Llandysul, Wales
- 8 Galway, Ireland
- 9 Camberley and Farnham, England
- 10 **Worldwide Headquarters:** London, England
- 11 Düsseldorf, Germany

Asia

- 12 Istanbul, Turkey
- 13 Yokneam, Israel
- 14 Hong Kong
- 15 Taipei, Taiwan

Australia

- 16 Adelaide, SA



Our Products

BTG products mentioned may not be available in every region.

Interventional Oncology

Bead Block®

DC Bead®

DC Bead LUMI™

IO Ablation®

LC Bead®

LC Bead LUMI™

TheraSphere®

Vascular

BTG Crossing Devices

BTG Sentry

EKOS® Endovascular System

Varithena® (polidocanol injectable foam) 1%

Pharmaceuticals

CroFab® (crotalidae polyvalent immune fab (ovine))

DigiFab® (digoxin immune fab (ovine))

Voraxaze® (glucarpidase)

Contact Information

Headquarters | London

Tel: +44 (0)20 7575 0000

Email: info@btgplc.com

© 2018 BTG International Ltd. All rights reserved. "Imagine where we can go," BTG and the BTG roundel logo are trademarks and/or registered trademarks of BTG International Ltd. Bead Block, DC Bead, DC BeadM1, DC Bead LUMI, LC Bead, LC BeadM1, LC Bead LUMI, LUMI, Simplicit90Y, IO Loop and IO Ablation are trademarks and/or registered trademarks of Biocompatibles UK Ltd. EKOS is a trademark and/or registered trademark of EKOS Corporation. GALIL, ICEROD, ITHAW, ICESPHERE, ICESSEED, IceEDGE, VISUAL-ICE, ICEORCE, ICEPEARL, ICEFX are trademarks and/or registered trademarks of Galil Medical Ltd. PneumRx is a trademark and/or registered trademark of PneumRx, Inc. TheraSphere is a trademark and/or registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. Varithena is a trademark and/or registered trademark of Provensis Ltd. CroFab and DigiFab are trademarks and/or registered trademarks of BTG International, Inc. Voraxaze is a trademark and/or registered trademark of Protherics Medicines Development Ltd. SnakeBite911 and the SnakeBite911 logo are trademarks and/or registered trademarks of Protherics UK Ltd. MicroCross, CenterCross and MultiCross are trademarks and/or registered trademarks of Roxwood Medical, Inc. BTG Sentry is a trademark and/or registered trademark of Novate Medical Limited. Lemtrada is a trademark and/or registered trademark of Genzyme Corporation. Zytiga is a trademark and/or registered trademark of Johnson & Johnson. Biocompatibles UK Ltd, EKOS Corporation, Galil Medical Ltd, Novate Medical Limited, PneumRx, Inc., Protherics Medicines Development Ltd, Protherics UK Ltd, Provensis Ltd and Roxwood Medical Inc are all BTG International group companies

Please refer to our website for other locations and more detailed contact information.

Not all products and/or indications are available in all territories. For prescribing information, safety information, and/or product information, go to: bead-block.com | crofab.com | dcbead.com | dcbeadlumi.com | digiFab.us | ekoscorp.com | galilmedical.com | lcbead.com | lcbeadlumi.com | pneumrx.com | thersphere.com | varithena.com | voraxaze.com

All information correct as of December 2018